Season 1 · Episode 23
Ep. 23 Jason Foster on Scaling Indivior, Leading Ori Biotech, and Solving the Real-World Bottlenecks Holding Back Cell and Gene Therapy
April 6, 202556m 34s
Audio is streamed directly from the publisher (redirect.zencastr.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
This week we are joined by Jason Foster, CEO of Ori Biotech to talk about the future of CGT and why scalable strategic manufacturing is in a make or break moment, his experience scaling Indivior from 5 to 1,100 people culminating in a £3B exit and the powerful culture behind that growth, the Bluebird Bio acquisition and what it means for CGT investment today, and why he is deeply optimistic about Ori Biotech’s automated, closed platform. A must-listen for anyone building, investing in, or scaling the next era of biotech.
Topics
CellAndGeneTherapyBiotechInnovationOriBiotechJasonFosterBiotechLeadershipScalingBiotechCGTBiotechManufacturingIndiviorBluebirdBioBiotechInvestingAutomatedBiotechClosedPlatformBiotechExitBiotechCultureFutureOfBiotechBiotechStrategyBiotechPodcastHealthcareInnovationLifeSciences